Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New camera could save hearts: OCTAVE trial tests smarter stent placement

NCT ID NCT07422688

Disease control Sponsor: Aarhus University Hospital Skejby Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 17, 2026 · Updated 12 times

Summary

This study tests whether using a special camera (OCT) inside the heart's arteries during a heart attack procedure leads to better outcomes than the standard X-ray method. About 3000 people having a heart attack will be randomly assigned to one of the two approaches. The goal is to see if OCT guidance reduces deaths, heart attacks, and strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Optical coherence tomography (OCT) imaging guidance during stent placement
What this could lead to
If successful, this could show that using OCT imaging during heart attack procedures reduces the risk of death, heart attacks, and strokes compared to standard X-ray guidance.
What could go wrong
This is a large trial, but OCT is an additional procedure that may not improve outcomes enough to justify its cost and time. There is also a risk of complications from the imaging itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2039

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Clinical inclusion criteria: * NSTEMI, STEMI * Symptom duration \<12h for STEMI and \<48h for NSTEMI * Age ≥ 18yrs * Ability to provide written informed consent Angiographic inclusion criteria: * Angiographic signs of at least one possible culprit lesion. Signs including acute occlusion, partial occlusion, proximal embolus, haziness, high grade stenosis, stent thrombosis * Wire in true distal lumen Exclusion Criteria: Clinical exclusion criteria * Intravascular imaging evaluation of any lesions at index procedure * Cardiogenic shock * Sustained ventricular tachycardia or ventricular fibrillation * Planned CABG * Life expectancy \<1 year * Known severe heart failure with NYHA class equal or above III * Known ejection fraction \<30% before the admission * Known renal failure with GFR \<30 ml/min/1.73 m2 * Active bleeding or coagulopathy * Relevant allergies (contrast media, aspirin, clopidogrel, ticagrelor, everolimus) * Suspected inability to lie flat for the duration of the PCI procedure * Inability to comply with the planned follow-up program * Known or anticipated compliance problems with medical therapy Angiographic exclusion criteria * Study lesion involving the Left main coronary artery * Study lesion involving a true bifurcation lesion with a SB \>2.5mm * Severe tortuosity * Distal embolus * Isolated coronary artery spasm * Suspected spontaneous coronary artery dissection * Chronic total occlusions with treatment indication and no antegrade intra plaque wire pass

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acs (acute coronary syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute chest syndrome acute coronary syndrome coronary artery disorder myocardial ischemia ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acs (acute coronary syndrome) Ischemic coronary artery disease Ischemic heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites in 12 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, 9100, Denmark

  • Aarhus University Hospital Skejby

    Aarhus N, 8200, Denmark

  • Akademiske Sjukhuset

    Uppsala, 75237, Sweden

  • Akerhus University Hospital - AHUS

    Lørenskog, 1478, Norway

  • Auckland City Hospital

    Auckland, 1023, New Zealand

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital of Southern Norway, Arendal

    Arendal, 4604, Norway

  • Karolinska Universitetssjukhuset

    Stockholm, 14157, Sweden

  • Kuopio University Hospital

    Kuopio, 70210, Finland

  • Latvia Centre of Cardiology

    Riga, LV-1002, Latvia

  • Leuven University Hospital

    Leuven, 3000, Belgium

  • North Karelia Central Hospital

    Joensuu, Finland

  • North-Estonia Medical Centre

    Tallinn, 13419, Estonia

  • Odense University Hospital

    Odense, 5000, Denmark

  • Rigshospitalet

    København Ø, 2100, Denmark

  • Royal Bournemouth Hospital

    Bournemouth, BH77DW, United Kingdom

  • Sahlgrenska University Hospital

    Gothenburg, 41345, Sweden

  • St Bartholomew's Hospital

    London, EC1A 7BE, United Kingdom

  • Sunderby Sjukhus

    Luleå, 97180, Sweden

  • Turin Nord Emergency Hospital

    Turin, 10154, Italy

  • University Hospital of Zürich

    Zurich, 8091, Switzerland

  • Zealand University Hospital, Roskilde Sygehus

    Roskilde, 4000, Denmark

  • Ziekenhuis Oost-Limburg

    Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.